- Home
- SPMA vs XOMAP Comparison
SPMA vs XOMAP Comparison
Compare SPMA & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPMA | XOMAP |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | 14 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SPMA | XOMAP |
|---|---|---|
| Price | $25.20 | $25.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.5K | ★ 4.7K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.46 | $25.14 |
| 52 Week High | $25.60 | $27.30 |
Technical Indicators
Market Signals| Indicator | SPMA | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 42.86 |
| Support Level | $25.00 | $25.12 |
| Resistance Level | $25.31 | $26.12 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 45.45 | 21.43 |
Price Performance
Historical ComparisonAbout SPMA Sound Point Meridian Capital Inc.
Sound Point Meridian Capital Inc is a closed-end management investment company. The Company's primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.